(Q38402469)

English

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK01

scientific article published on 07 July 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK01 (English)

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

phase III clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ursula Vehling-Kaiser

2

object named as

Ursula Vehling-Kaiser

0 references

Ludwig Fischer von Weikersthal

10

object named as

Ludwig Fischer von Weikersthal

0 references

Susanna Hegewisch-Becker

14

object named as

Susanna Hegewisch-Becker

0 references

author name string

Volker Heinemann

1

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Dirk Waldschmidt

3

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Erika Kettner

4

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Angela Märten

5

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Cornelia Winkelmann

6

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Stefan Klein

7

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Georgi Kojouharoff

8

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Thomas C Gauler

9

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Michael R Clemens

11

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Michael Geissler

12

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Tim F Greten

13

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Oleg Rubanov

15

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Gerold Baake

16

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Thomas Höhler

17

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Yon D Ko

18

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Andreas Jung

19

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Sascha Neugebauer

20

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Stefan Boeck

21

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

language of work or name

0 references

publication date

7 July 2012

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

62

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

5

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

751-759

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Global cancer statistics

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22773551

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/GUTJNL-2012-302759

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

2 July 2019

http://europepmc.org/abstract/PMC/6309814

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38402469&oldid=1570019466"